Skip to content
VuFind
Advanced
  • Does Chinese Medical Insurance...
  • Cite this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
Does Chinese Medical Insurance System Affect Selection of Rituximab Therapy Among Patients with Non-Hodgkin Lymphoma?
QR Code

Does Chinese Medical Insurance System Affect Selection of Rituximab Therapy Among Patients with Non-Hodgkin Lymphoma?

Bibliographic Details
Main Authors: Jian, Le, Huang, Y.
Other Authors: Kshanika Hirimburegama
Format: Conference Paper
Published: University of Colombo 2012
Online Access:http://hdl.handle.net/20.500.11937/27987
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://hdl.handle.net/20.500.11937/27987

Similar Items

  • Socioeconomic Inequality in the Use of Rituximab Therapy Among Non-Hodgkin Lymphoma Patients in Chinese Public Hospitals
    by: Huang, Y., et al.
    Published: (2012)
  • In-House Radio-Labelling Of 131i-Rituximab In Threatment Of Cd20+ B-Cell Non-Hodgkin’s Lymphoma: A Pioneer Experience In Malaysia
    by: Kuan, Jew Win, et al.
    Published: (2016)
  • A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant
    by: Jew, Win Kuan, et al.
    Published: (2016)
  • Non-neoformans cryptococcemia in a patient with hodgkin’s lymphoma
    by: Ding, Chuanhun, et al.
    Published: (2018)
  • Clinical association with non-hodgkin lymphoma
    by: Abdullah, Wan Zaidah
    Published: (2004)

Search Options

  • Advanced Search

Find More

  • Browse the Catalog

Need Help?

  • Search Tips